Cognex
CGNX
44.36
-3.30
-6.92%
Cognex
US · CGNX
#1393 by market cap
Listed 1970
44.36
-3.30
-6.92%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 9.89, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +8.73% YoY
Margins
- Gross margin
- 66.92%
- Operating margin
- 16.35%
- Net margin
- 11.51%
Key ratios & quality
- Altman Z-Scorei
- 9.89
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 806.34M | 725.63M | 811.02M | 1.04B | 1.01B | 837.55M | 914.52M | 994.36M |
| Gross profit | 600.29M | 535.87M | 604.60M | 759.83M | 721.91M | 601.24M | 625.79M | 665.39M |
| Selling & admin expenses | 262.70M | 273.84M | 267.59M | 309.35M | 312.11M | 339.14M | 370.91M | 363.86M |
| Research & development | 116.45M | 119.43M | 130.98M | 135.37M | 141.13M | 139.40M | 139.82M | 138.97M |
| Operating profit | 221.14M | 142.60M | 206.02M | 315.10M | 268.67M | 122.70M | 115.07M | 162.57M |
| Pretax profit | 234.57M | 162.99M | 186.91M | 318.90M | 250.70M | 135.35M | 131.49M | 182.80M |
| Tax | 15.31M | -40.87M | 10.73M | 39.02M | 35.17M | 22.11M | 25.32M | 68.36M |
| Net profit | 219.27M | 203.87M | 176.19M | 279.88M | 215.53M | 113.23M | 106.17M | 114.44M |
| Basic EPS | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 |
| Diluted EPS | 1.24 | 1.16 | 1.00 | 1.56 | 1.23 | 0.65 | 0.62 | 0.68 |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-04 | 2026-07 | 2026-10 |
|---|---|---|---|---|---|---|
| Revenue | 249.09M | 276.89M | 252.34M | 268.44M | 291.26M | 313.39M |
| Gross profit | 167.88M | 187.29M | 165.90M | 190.94M | 205.77M | 221.74M |
| Selling & admin expenses | 91.34M | 94.44M | 94.57M | 94.04M | 87.87M | 87.02M |
| Research & development | 33.10M | 35.08M | 36.06M | 37.03M | 32.39M | 33.90M |
| Operating profit | 43.43M | 57.77M | 35.28M | 59.87M | 85.52M | 100.82M |
| Pretax profit | 48.06M | 62.86M | 44.08M | 61.76M | 89.30M | 103.29M |
| Tax | 7.55M | 45.20M | 11.42M | 10.05M | 16.54M | 18.47M |
| Net profit | 40.51M | 17.66M | 32.66M | 51.70M | 72.76M | 84.82M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 1 |
| Diluted EPS | 0.24 | 0.10 | 0.19 | 0.31 | 0.43 | 0.50 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 780.33M | 607.23M | 601.69M | 639.80M | 717.70M | 679.00M | 613.37M | 697.25M |
| Cash & ST investments | 535.56M | 411.90M | 372.31M | 323.62M | 400.13M | 332.05M | 246.05M | 336.96M |
| Inventory | 83.28M | 60.26M | 60.83M | 113.10M | 122.48M | 162.29M | 157.53M | 137.89M |
| Total assets | 1.29B | 1.89B | 1.80B | 2.00B | 1.96B | 2.02B | 1.99B | 2.02B |
| Total current liabilities | 91.36M | 120.48M | 132.30M | 188.59M | 187.71M | 151.88M | 169.38M | 183.55M |
| Short-term debt | -- | 5.65M | 8.11M | 7.79M | 8.45M | 9.62M | 8.85M | 11.72M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 154,404,000.00 | 530,225,000.00 | 538,500,000.00 | 573,569,000.00 | 519,746,000.00 | 513,060,000.00 | 475,345,000.00 | 524,654,000.00 |
| Total equity | 1.14B | 1.36B | 1.26B | 1.43B | 1.44B | 1.50B | 1.52B | 1.49B |
| Retained earnings | 646.21M | 753.27M | 487.91M | 562.88M | 528.18M | 512.54M | 499.30M | 406.36M |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-04 | 2026-07 | 2026-10 |
|---|---|---|---|---|---|---|
| Total current assets | 625.73M | 670.92M | 697.25M | 690.35M | 849.88M | 1.15B |
| Cash & ST investments | 228.20M | 300.27M | 336.96M | 296.76M | 404.37M | 695.69M |
| Inventory | 144.58M | 143.68M | 137.89M | 135.55M | 142.84M | 158.45M |
| Total assets | 2.00B | 2.00B | 2.02B | 2.01B | 2.18B | 2.28B |
| Total current liabilities | 190.44M | 169.27M | 183.55M | 189.49M | 216.03M | 228.72M |
| Short-term debt | 11.26M | 10.61M | 11.72M | 12.31M | 12.28M | 12.31M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 497,484,000.00 | 513,114,000.00 | 524,654,000.00 | 526,649,000.00 | 549,095,000.00 | 554,977,000.00 |
| Total equity | 1.51B | 1.49B | 1.49B | 1.48B | 1.63B | 1.72B |
| Retained earnings | 433.04M | 412.35M | 406.36M | 344.44M | 397.14M | 467.65M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 223.45M | 253.31M | 242.40M | 314.07M | 243.41M | 112.92M | 149.08M | 245.51M |
| Depreciation & amortization | 21.55M | 24.90M | 26.50M | 20.28M | 19.62M | 21.88M | 32.69M | 30.79M |
| Free cash flow | 186.36M | 231.57M | 229.10M | 298.61M | 223.74M | 89.84M | 134.04M | 236.77M |
| Dividends paid | -31.87M | -35.12M | -390.51M | -43.26M | -45.92M | -49.08M | -52.33M | -54.63M |
| Stock buybacks / issuance | -203.82M | -61.69M | -51.04M | -161.65M | -204.31M | -79.79M | -67.09M | -151.23M |
| Ending cash balance | 108.21M | 171.43M | 269.07M | 186.16M | 181.37M | 202.66M | 186.09M | 262.93M |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-04 | 2026-07 | 2026-10 |
|---|---|---|---|---|---|---|
| Operating cash flow | 42.63M | 87.49M | 74.90M | 45.09M | 69.15M | 106.42M |
| Depreciation & amortization | 8.00M | 7.53M | 7.33M | 7.24M | 6.88M | 6.82M |
| Free cash flow | 40.43M | 86.03M | 72.31M | 42.34M | 67.62M | 103.78M |
| Dividends paid | -13.43M | -13.44M | -14.20M | -14.20M | -14.26M | -14.31M |
| Stock buybacks / issuance | 0 | -24.00M | -25.00M | -99.00M | -6.24M | 0 |
| Ending cash balance | 179.31M | 245.90M | 262.93M | 237.34M | 302.52M | 694.70M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 19.66 | 16.37 | 13.46 | 20.79 | 15.03 | 7.69 | 7.03 | 7.61 |
| ROA %i | 17.01 | 12.84 | 9.56 | 14.71 | 10.88 | 5.70 | 5.29 | 5.71 |
| ROIC %i | 19.66 | 16.14 | 13.24 | 20.40 | 14.69 | 7.40 | 6.70 | 7.25 |
| 5-year avg ROE %i | 18.89 | 18.64 | 16.55 | 17.49 | 17.06 | 14.67 | 12.80 | 11.63 |
| EBIT margin %i | 27.43 | 19.65 | 25.40 | 30.38 | 26.70 | 14.65 | 12.58 | 16.35 |
| FCF / sales %i | 23.11 | 31.90 | 28.25 | 28.79 | 22.24 | 10.73 | 14.66 | 23.81 |
| Current ratioi | 8.54 | 5.04 | 4.55 | 3.39 | 3.82 | 4.47 | 3.62 | 3.80 |
| Quick ratioi | 7.26 | 4.32 | 3.81 | 2.43 | 2.81 | 2.95 | 2.32 | 2.73 |
| Debt / assetsi | 0.00 | 0.95 | 1.46 | 1.28 | 2.03 | 3.90 | 3.52 | 3.80 |
| LT debt / equityi | -- | 0.91 | 1.44 | 1.24 | 2.18 | 4.58 | 4.04 | 4.35 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | 21.41 | 11.07 | 1.92 | 8.75 | 11.51 | 1.08 | -4.11 | -0.39 |
| Net income CAGR (3Y) %i | 5.44 | 12.37 | -0.10 | 8.48 | 1.87 | -13.70 | -27.61 | -19.02 |
| FCF CAGR (3Y) %i | 23.21 | 11.01 | 5.42 | 17.02 | -1.14 | -26.80 | -23.43 | 1.91 |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-04 | 2026-07 | 2026-10 |
|---|---|---|---|---|---|---|
| ROE %i | 8.10 | 7.21 | 7.61 | 9.75 | 11.15 | 15.07 |
| ROA %i | 6.09 | 5.42 | 5.71 | 7.24 | 8.36 | 11.31 |
| ROIC %i | 7.70 | 6.86 | 7.25 | 9.28 | 10.62 | 14.40 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 14.19 | 16.27 | 16.35 | 18.76 | 21.90 | 25.01 |
| FCF / sales %i | 19.32 | 22.00 | 23.81 | 23.03 | 24.64 | 25.42 |
| Current ratioi | 3.29 | 3.96 | 3.80 | 3.64 | 3.93 | 5.04 |
| Quick ratioi | 2.18 | 2.79 | 2.73 | 2.55 | 2.93 | 4.05 |
| Debt / assetsi | 4.15 | 3.94 | 3.80 | 3.69 | 3.33 | 3.09 |
| LT debt / equityi | 4.78 | 4.59 | 4.35 | 4.17 | 3.69 | 3.37 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Machine vision technology100.00%
Quote time 2026-11-20 20:02:15 · For reference only, not investment advice and not tailored to your situation.
Cognex discussion 0 comments